Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

5(83.3%)

N/A

1(16.7%)

6Total

Phase 4(5)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01269125Not ApplicableCompleted

GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.

Role: collaborator

NCT01472497Phase 4Completed

Effects of Pioglitazone in Hypertensive Patients

Role: lead

NCT00663494Completed

Matrix Metalloproteinase (MMP) in Heart Failure

Role: lead

NCT00664222Phase 4Completed

Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)

Role: lead

NCT00663195Phase 4Completed

Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure

Role: lead

NCT00663377Phase 4Completed

Effects of Losartan on Insulin Resistance in Patients With Heart Failure

Role: lead

NCT00422318Phase 4Completed

Treatment of Hyperuricemia in Patients With Heart Failure

Role: lead

All 7 trials loaded